BioSpace News Archive

Acurx Pharmaceuticals, Inc. announced today that the Company will release its 2022 third quarter financial results on Monday, November 14, 2022, at 8:30 am ET before the U.S. financial markets open.

Echosens Presents Robust Research at 2022 AASLD Liver Meeting: Noninvasive FibroScan ® Technology Recognized as Critical Component to Optimize Liver Health Management.

Bausch Health Companies Inc. today announced the presentation of nine posters during the Innovations in Dermatology Conference, which takes place Nov. 3-5, 2022, in Las Vegas, Nev.

Apex Labs Ltd. (“APEX” or the “Company”) is pleased to announce its approval for the first North American take home multi-dose psilocybin clinical trial, APEX-002-A01-02, evaluating the safety and efficacy of APEX-52 (psilocybin) in treating depression in Veterans with Post Traumatic Stress Disorder (“PTSD”).

T2 Biosystems, Inc. today announced that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on October 31, 2022 informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market.

Eterna Therapeutics Inc. today announced it has entered into a sponsored research agreement with Michael Andreeff, M.D., Ph.D., Professor of Leukemia at The University of Texas MD Anderson Cancer Center (“MD Anderson”).

SCYNEXIS, Inc. today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2022.

Quoin Pharmaceuticals Ltd. announced today that its third quarter 2022 financial results will be reported on Thursday, November 10, 2022 before the open of the financial markets.

Pyxis Oncology, Inc. reported financial results for the third quarter and nine months ended September 30, 2022 and provided a corporate update.

Pfizer Inc. announced positive top-line data from the Phase 3 clinical trial MATISSE investigating its bivalent RSV prefusion vaccine candidate, RSVpreF or PF-06928316, when administered to pregnant participants to help protect their infants from RSV disease after birth.